154 related articles for article (PubMed ID: 29277681)
1. Enhanced antitumor and anti-metastasis efficacy against aggressive breast cancer with a fibronectin-targeting liposomal doxorubicin.
Jiang K; Song X; Yang L; Li L; Wan Z; Sun X; Gong T; Lin Q; Zhang Z
J Control Release; 2018 Feb; 271():21-30. PubMed ID: 29277681
[TBL] [Abstract][Full Text] [Related]
2. Integrin α
Zhou B; Li M; Xu X; Yang L; Ye M; Chen Y; Peng J; Xiao L; Wang L; Huang S; Zhang L; Lin Q; Zhang Z
Mol Pharm; 2021 Jul; 18(7):2634-2646. PubMed ID: 34134485
[TBL] [Abstract][Full Text] [Related]
3. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin-loaded nanocarriers: A comparative study of liposome and nanostructured lipid carrier as alternatives for cancer therapy.
Fernandes RS; Silva JO; Monteiro LOF; Leite EA; Cassali GD; Rubello D; Cardoso VN; Ferreira LAM; Oliveira MC; de Barros ALB
Biomed Pharmacother; 2016 Dec; 84():252-257. PubMed ID: 27664949
[TBL] [Abstract][Full Text] [Related]
5. The antitumor activity of tumor-homing peptide-modified thermosensitive liposomes containing doxorubicin on MCF-7/ADR: in vitro and in vivo.
Wang C; Wang X; Zhong T; Zhao Y; Zhang WQ; Ren W; Huang D; Zhang S; Guo Y; Yao X; Tang YQ; Zhang X; Zhang Q
Int J Nanomedicine; 2015; 10():2229-48. PubMed ID: 25834435
[TBL] [Abstract][Full Text] [Related]
6. Enhanced antitumor and anti-metastasis efficiency via combined treatment with CXCR4 antagonist and liposomal doxorubicin.
Mei L; Liu Y; Zhang Q; Gao H; Zhang Z; He Q
J Control Release; 2014 Dec; 196():324-31. PubMed ID: 25450404
[TBL] [Abstract][Full Text] [Related]
7. PEGylated liposomal doxorubicin targeted to α5β1-expressing MDA-MB-231 breast cancer cells.
Shroff K; Kokkoli E
Langmuir; 2012 Mar; 28(10):4729-36. PubMed ID: 22268611
[TBL] [Abstract][Full Text] [Related]
8. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
Moosavian SA; Abnous K; Badiee A; Jaafari MR
Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
[TBL] [Abstract][Full Text] [Related]
9. Lipopepsomes: A novel and robust family of nano-vesicles capable of highly efficient encapsulation and tumor-targeted delivery of doxorubicin hydrochloride in vivo.
Qiu M; Sun H; Meng F; Cheng R; Zhang J; Deng C; Zhong Z
J Control Release; 2018 Feb; 272():107-113. PubMed ID: 29355618
[TBL] [Abstract][Full Text] [Related]
10. Multiple sessions of liposomal doxorubicin delivery via focused ultrasound mediated blood-brain barrier disruption: a safety study.
Aryal M; Vykhodtseva N; Zhang YZ; McDannold N
J Control Release; 2015 Apr; 204():60-9. PubMed ID: 25724272
[TBL] [Abstract][Full Text] [Related]
11. Targeting, bio distributive and tumor growth inhibiting characterization of anti-HER2 affibody coupling to liposomal doxorubicin using BALB/c mice bearing TUBO tumors.
Akhtari J; Rezayat SM; Teymouri M; Alavizadeh SH; Gheybi F; Badiee A; Jaafari MR
Int J Pharm; 2016 May; 505(1-2):89-95. PubMed ID: 27039149
[TBL] [Abstract][Full Text] [Related]
12. Low molecular weight heparin-based reduction-sensitive nanoparticles for antitumor and anti-metastasis of orthotopic breast cancer.
Sun H; Cao D; Liu Y; Wang H; Ke X; Ci T
Biomater Sci; 2018 Jul; 6(8):2172-2188. PubMed ID: 29942949
[TBL] [Abstract][Full Text] [Related]
13. Phytosterol-loaded CD44 receptor-targeted PEGylated nano-hybrid phyto-liposomes for synergistic chemotherapy.
Gautam M; Thapa RK; Gupta B; Soe ZC; Ou W; Poudel K; Jin SG; Choi HG; Yong CS; Kim JO
Expert Opin Drug Deliv; 2020 Mar; 17(3):423-434. PubMed ID: 32028805
[No Abstract] [Full Text] [Related]
14. In vivo study of doxorubicin-loaded cell-penetrating peptide-modified pH-sensitive liposomes: biocompatibility, bio-distribution, and pharmacodynamics in BALB/c nude mice bearing human breast tumors.
Ding Y; Cui W; Sun D; Wang GL; Hei Y; Meng S; Chen JH; Xie Y; Wang ZQ
Drug Des Devel Ther; 2017; 11():3105-3117. PubMed ID: 29123382
[TBL] [Abstract][Full Text] [Related]
15. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.
Arabi L; Badiee A; Mosaffa F; Jaafari MR
J Control Release; 2015 Dec; 220(Pt A):275-286. PubMed ID: 26518722
[TBL] [Abstract][Full Text] [Related]
16. Enhanced doxorubicin delivery to hepatocellular carcinoma cells via CD147 antibody-conjugated immunoliposomes.
Wang J; Wu Z; Pan G; Ni J; Xie F; Jiang B; Wei L; Gao J; Zhou W
Nanomedicine; 2018 Aug; 14(6):1949-1961. PubMed ID: 29045824
[TBL] [Abstract][Full Text] [Related]
17. Robust, tumor-homing and redox-sensitive polymersomal doxorubicin: A superior alternative to Doxil and Caelyx?
Zou Y; Meng F; Deng C; Zhong Z
J Control Release; 2016 Oct; 239():149-58. PubMed ID: 27569664
[TBL] [Abstract][Full Text] [Related]
18. Heparan sulfate targeting strategy for enhancing liposomal drug accumulation and facilitating deep distribution in tumors.
Kuo PH; Teng YH; Cin AL; Han W; Huang PW; Wang LH; Chou YT; Yang JL; Tseng YL; Kao M; Chang MD
Drug Deliv; 2020 Dec; 27(1):542-555. PubMed ID: 32241176
[TBL] [Abstract][Full Text] [Related]
19. Primary tumor and pre-metastatic niches co-targeting "peptides-lego" hybrid hydroxyapatite nanoparticles for metastatic breast cancer treatment.
Xiong H; Du S; Zhang P; Jiang Z; Zhou J; Yao J
Biomater Sci; 2018 Sep; 6(10):2591-2604. PubMed ID: 30187035
[TBL] [Abstract][Full Text] [Related]
20. Folate receptor-targeted multimodal polymersomes for delivery of quantum dots and doxorubicin to breast adenocarcinoma: In vitro and in vivo evaluation.
Alibolandi M; Abnous K; Sadeghi F; Hosseinkhani H; Ramezani M; Hadizadeh F
Int J Pharm; 2016 Mar; 500(1-2):162-78. PubMed ID: 26802496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]